Cefixime
Cefixime
- In our pharmacy, you can buy cefixime without a prescription, with delivery in 5–14 days throughout the United Kingdom. Discreet and anonymous packaging.
- Cefixime is a third‑generation oral cephalosporin antibiotic used to treat bacterial infections such as respiratory tract infections, otitis media, pharyngitis, uncomplicated urinary tract infections and gonorrhoea; it works by inhibiting bacterial cell‑wall synthesis (binding penicillin‑binding proteins) and is bactericidal.
- The usual adult dose is 400 mg once daily or 200 mg every 12 hours, typically for 5–10 days depending on the infection; paediatric dosing is weight‑based—follow local prescribing guidelines.
- The form of administration is oral: film‑coated tablets/capsules or an oral suspension (liquid).
- The antibiotic begins bactericidal activity within a few hours after adequate blood levels are reached, with many patients noticing symptomatic improvement within 24–48 hours.
- The clinical duration of action supports once‑daily dosing (about 24‑hour coverage); the elimination half‑life is roughly 3–4 hours.
- Avoid alcohol while taking cefixime and during recovery, as alcohol may worsen side effects and impede recovery.
- The most common side effect is gastrointestinal upset, particularly diarrhoea; other common effects include nausea, abdominal pain and rash.
- Would you like to try cefixime without a prescription?
Basic Cefixime Information
- INN (International Nonproprietary Name): not specified
- Brand Names Available In United Kingdom: not specified
- ATC Code: not specified
- Forms & Dosages: Film-coated tablets (250mg, 500mg, 1000mg); Effervescent/suspension (125mg/5ml, 250mg/5ml); Solution for injection (500mg/50ml, 1g/100ml); Suppositories (80mg, 150mg, 300mg).
- Manufacturers In United Kingdom: Local manufacturers such as Zentiva and Biofarm are listed as examples in source material; specific UK suppliers are not specified.
- Registration Status In United Kingdom: not specified
- OTC / Rx Classification: Prescription (Rx) in most regions.
Latest Research Highlights (UK And EU)
What are clinicians and patients most worried about right now?
Surveillance reports across the UK and EU from 2021 to 2024 consistently flag rising reduced susceptibility in Enterobacterales and Neisseria gonorrhoeae to oral third‑generation cephalosporins.
High‑quality randomised controlled trials supporting oral cefixime as first‑line therapy for severe or invasive infections are limited in 2022–2025 literature.
| Study / Report | Design & Population | Primary Outcome | Safety Signals |
|---|---|---|---|
| UKHSA And National AMR Surveillance Summaries (2021–2024) | National surveillance; gonococcal and Enterobacterales isolates | Increased azithromycin/cephalosporin resistance in gonococci; rising Enterobacterales resistance | Reports of treatment failure with oral cephalosporins; routine GI adverse events |
| ECDC And EMA Reviews (2022–2024) | European surveillance and pharmacovigilance datasets | Regional heterogeneity; guideline shifts away from oral cefixime for uncomplicated gonorrhoea | Low but notable Clostridioides difficile association in older adults |
| Cochrane/Systematic Reviews (2022–2024) | Meta-analyses of RCTs for paediatric RTI/otitis media | Modest superiority over placebo in selected subgroups; limited generalisability | GI upset and rare hypersensitivity noted across trials |
| EU Pharmacoepidemiology Projects (2023–2024) | Community prescribing cohorts and outcome monitoring | Exploring drivers of community cefixime use and outcomes | Ongoing signal detection for severe allergic events via EudraVigilance |
Data Highlights
- UKHSA and ECDC surveillance show increased reduced susceptibility in gonococci to oral third‑generation cephalosporins, prompting guideline changes.
- Paediatric outpatient trials still support oral cefixime as an alternative for otitis media or respiratory infections when penicillin allergy exists, but effect sizes are modest.
- Safety monitoring via MHRA Yellow Card and EudraVigilance consistently records gastrointestinal events, rare severe hypersensitivity, and a small but important C. difficile association in older adults.
Clinical Effectiveness In The UK
Will cefixime work for my condition in NHS practice?
Cefixime performs well when the infecting organism is known to be susceptible and when used for appropriate indications.
- Uncomplicated Urinary Tract Infection
- Used when culture confirms susceptibility.
- Otitis Media And Respiratory Tract Infection
- Alternative oral therapy for penicillin‑allergic patients in community settings.
- Gonorrhoea
- Historical oral option now largely not recommended empirically because of resistance concerns.
| Outcome | Typical Result In NHS Practice |
|---|---|
| Cure Rates (Susceptible Organisms) | High clinical cure when guided by local antibiogram and microbiology advice. |
| Relapse / Treatment Failure | More likely with ESBL‑producing Enterobacterales or in areas with local resistance. |
| Adverse Events | Gastrointestinal upset most common; rare severe hypersensitivity; watch for C. difficile in older adults. |
Patient adherence is generally good thanks to simple once‑daily or twice‑daily regimens.
Empirical use without susceptibility data increases risk of therapeutic failure in higher‑resistance areas.
Indications And Expanded Uses
When is cefixime licensed for use in the UK, and when might it be used off‑label?
MHRA‑classified indications for oral cefixime are typically limited to infections caused by susceptible organisms and vary by product licence.
- MHRA‑Approved Uses: Uncomplicated lower respiratory tract infections; uncomplicated urinary tract infections; otitis media; pharyngitis/tonsillitis caused by susceptible bacteria.
- Important NHS Note: Not recommended empirically for gonorrhoea in contemporary UKHSA guidance due to resistance concerns; parenteral ceftriaxone preferred for most gonorrhoeal infections.
Off‑Label Uses
- Step‑down oral therapy after intravenous third‑generation cephalosporins for selected stable infections with susceptible organisms.
- Treatment or eradication in rare meningococcal carriage contexts, where advised by specialists.
- All off‑label prescribing should follow microbiology advice, local formulary guidance and informed consent documentation.
Composition And Brand Landscape
Which formulations and brands do pharmacies and the NHS commonly supply?
| Formulation | Strength | Typical Pack Sizes | Typical UK Suppliers / Brands |
|---|---|---|---|
| Tablets | 200 mg | 5–14 tablets | Generic manufacturers (varies by supplier) |
| Tablets | 400 mg | 5–14 tablets | Generic manufacturers (varies by supplier) |
| Oral Suspension | 40 mg/mL (example paediatric strength) | 30–100 mL bottles | Generic paediatric formulations |
Active ingredient: cefixime (INN), a third‑generation cephalosporin.
Branded product examples internationally include Suprax, though UK availability of that brand varies and multiple generics supply the NHS and community pharmacies.
Packaging and availability are driven by NHS supplier contracts and wholesale stock levels.
Contraindications And Special Precautions
Who should avoid cefixime, and who requires extra monitoring?
- Absolute Contraindications: Known hypersensitivity to cefixime, other cephalosporins, or a history of severe anaphylaxis to beta‑lactams.
- Allergy Notes: Cross‑reactivity between penicillins and cephalosporins is low but possible; exercise caution and seek allergy specialist advice in severe penicillin allergy.
- Renal Impairment: Dose adjustment required for severe renal dysfunction; monitor renal function.
- Elderly: Increased risk of C. difficile infection and dehydration; monitor closely.
- Gastrointestinal Disease: Avoid or use with caution in patients with a history of severe colitis.
Pregnancy And Breastfeeding
Cefixime may be used in pregnancy when the clinician judges the benefit outweighs any potential risk.
Small amounts are excreted in breast milk; monitor breastfed infants for diarrhoea or thrush.
| Comorbidity | Caution |
|---|---|
| Severe Renal Impairment | Adjust dose per renal function; consult SPC or microbiology |
| History Of C. difficile | Avoid if possible; monitor for recurrence |
| Severe Beta‑Lactam Allergy | Consider alternative non‑beta‑lactam agents |
Dosage Guidelines
What dose should adults and children take, and how should renal impairment be managed?
| Population | Typical Dose | Notes / Maximum |
|---|---|---|
| Adults | 400 mg once daily or 200 mg twice daily | Follow local formulary; 400 mg/day commonly used; adjust per severity |
| Children | Approx. 8–12 mg/kg/day once daily or divided | Do not exceed adult maximum (usually 400 mg/day); refer to product licence |
| Renal Impairment | Reduce dose or extend interval for eGFR <50 mL/min | Consult SPC for exact renal adjustment tables |
Duration Of Therapy
- Uncomplicated UTI: 3–7 days depending on severity and clinical response.
- Otitis Media / RTI: 5–10 days guided by clinical course.
- Review therapy at 48–72 hours and stop if cultures show resistance or if clinical improvement is absent.
Interactions Overview
Which medicines and substances alter cefixime effect or safety?
- Probenecid: Raises cefixime plasma concentrations by reducing renal tubular secretion; relevant if monitoring toxicity.
- Antacids / H2 Blockers: May reduce absorption of some oral cephalosporins; advise separating doses where possible.
- Concomitant Nephrotoxins: Aminoglycosides, vancomycin and high‑dose diuretics increase renal monitoring needs when used with cephalosporins.
- Oral Contraceptives: No clinically significant interaction documented, but counsel that systemic illness may affect contraceptive reliability.
- Insulins / Oral Hypoglycaemics: Monitor blood glucose as acute infection or antibiotics can change glycaemic control.
Pharmacists should document interactions and counsel patients, and report suspected interaction‑related adverse reactions to MHRA Yellow Card.
Cultural Perceptions And Patient Habits In The UK
What do patients ask about cefixime on forums and in the pharmacy?
- Many patients see cefixime as a stronger oral antibiotic or as reserved for penicillin allergy or more serious infections.
- On community forums people commonly ask whether cefixime is effective for UTIs and express concerns about antimicrobial resistance.
- Trust in pharmacists is high, and many patients contact NHS 111 or their local pharmacist for advice before booking a GP appointment.
- Digital access via the NHS app and electronic prescriptions has increased convenience and prompted questions about generic versus branded choices and cost.
Example Patient Paraphrases
- "My GP suggested cefixime because I can't take amoxicillin — will it clear my ear infection?"
- "I read about resistance on forums; is cefixime still useful for gonorrhoea?"
- "Can the pharmacy give me cefixime quickly? I work weekends and can't see the GP." (Pharmacist explains stewardship and prescription rules.)
Availability And Pricing Patterns
How can patients access cefixime in the UK and what should they expect to pay?
| Supply Route | Access | Likely Wait Time | Cost Notes |
|---|---|---|---|
| NHS Prescription | Prescription‑only; subject to local formulary and GP decision | Same day to 2 days depending on GP and pharmacy | Charged per NHS prescription policy in England; free in many cases in Scotland, Wales, NI |
| Private Prescription Pharmacy | Prescription‑only; supplied against private prescription | Same day to 3 days | Price varies by pharmacy; generics reduce cost |
| Online Registered Pharmacies | Dispense against valid prescription with remote consultation | 2–7 days depending on verification and delivery | Generic options usually lower cost; stewardship limits repeat supplies |
In our online pharmacy, cefixime is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.
Major chains such as Boots and LloydsPharmacy stock generics according to wholesale and NHS contract supply; Superdrug availability varies by branch.
Comparable Medicines And Prescribing Preferences
Which antibiotics are preferred in NHS practice for common infections?
- Uncomplicated UTI: Nitrofurantoin or trimethoprim where susceptible are first‑line choices.
- Gonorrhoea: Parenteral ceftriaxone is preferred due to current resistance patterns.
- Community RTIs: Amoxicillin remains the mainstay for many bacterial respiratory infections.
| Indication | Preferred NHS First‑Line | When Cefixime Is Considered |
|---|---|---|
| Uncomplicated UTI | Nitrofurantoin / Trimethoprim (if susceptible) | When susceptibility confirmed or allergies prevent first‑line use |
| Gonorrhoea | Ceftriaxone (parenteral) | Oral cefixime generally not recommended empirically due to resistance |
| Community RTI | Amoxicillin | For penicillin allergy or specific susceptibility patterns |
Pros And Cons Checklist
- Pros: Oral dosing, useful for step‑down therapy, well tolerated in many patients.
- Cons: Broad spectrum that may drive resistance and C. difficile risk; not appropriate empirically for some infections.
Frequently Asked Questions
-
Can I take cefixime for a UTI without a test?
NHS guidance usually recommends urine testing or empirical first‑line agents guided by local resistance patterns.
Cefixime is reserved when susceptibility is known or a patient has a documented penicillin allergy.
-
Is cefixime safe during pregnancy?
Cefixime may be used when clinically necessary after a risk–benefit discussion with the prescriber and, where appropriate, obstetric team.
-
What if I miss a dose?
Take the missed dose as soon as you remember unless the next dose is due shortly.
Do not double up doses to catch up.
-
How do I report side effects?
Report suspected adverse reactions to the MHRA Yellow Card scheme via the app or website and inform the prescribing clinician.
Guidelines For Proper Use
What should pharmacists cover when counselling patients prescribed cefixime?
- Confirm the indication and review allergy history, especially to penicillins and cephalosporins.
- Check renal function and advise on dose adjustment if required.
- Discuss concomitant medications such as probenecid and antacids and advise on timing to avoid absorption issues.
- Explain the dosing schedule, duration, and expected timeline for symptom improvement (usually 48–72 hours for susceptible infections).
- Advise common side effects (nausea, diarrhoea, rash) and urgent signs (breathing difficulty, severe rash, persistent fever) that require immediate medical attention.
- Encourage reporting of adverse reactions to the MHRA Yellow Card and ensure follow‑up with the GP if symptoms persist.
Micro‑Leaflet Suggestions For Patients
- Heading: "About This Medicine — Cefixime".
- Short bullets: Why it was prescribed, how to take it, what to avoid, when to call the GP, and where to report side effects.
- Include NHS 111 and MHRA Yellow Card links and a reminder to complete the full course unless advised otherwise.
NHS Portal Links
- Advise use of NHS 111 for urgent advice and the NHS app for prescription records and repeat prescriptions.
- Remind patients that repeat antibiotic requests are subject to clinical review and antimicrobial stewardship policies.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 5-7 days |
| Birmingham | West Midlands | 5-7 days |
| Manchester | Greater Manchester | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Leeds | West Yorkshire | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Bristol | South West England | 5-7 days |
| Cardiff | Wales | 5-7 days |
| Belfast | Northern Ireland | 5-9 days |
| Newcastle | North East England | 5-9 days |
| Southampton | South East England | 5-9 days |
| Plymouth | South West England | 5-9 days |
| Norwich | East of England | 5-9 days |
| Kingston Upon Hull | East Yorkshire | 5-9 days |
Closing Practical Notes
Summary For Patients
Cefixime is an oral third‑generation cephalosporin used in defined situations where the causative organism is susceptible or where penicillin allergy limits options.
Always follow prescriber and pharmacist advice, complete the prescribed course unless instructed otherwise, and report any serious side effects to the MHRA Yellow Card scheme.
If symptoms do not improve within 48–72 hours, contact the GP or local urgent care service for review and possible culture testing.